Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors (NCT05985655)
A Phase 1/2 Open-label Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of GTAEXS617 in Patients With Advanced Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617 (REC-617) in participants with advanced solid tumors.
Who can join: Review the eligibility criteria below.
Location: USC Norris Comprehensive Cancer Center — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (15 Sites)
- USC Norris Comprehensive Cancer Center — Los Angeles, California
- START Midwest — Grand Rapids, Michigan
- Memorial Sloan Kettering Cancer Center — New York, New York
- The Ohio State University — Columbus, Ohio
- START San Antonio — San Antonio, Texas
- START Mountain Region — West Valley City, Utah
- GZA Ziekenhuizen - Campus Sint-Augustinus — Antwerp,
- Clinique Universitaires Saint-Luc — Brussels,
- Institute Jules Bordet — Brussels,
- CHU Sart Tilman — Liège,
- The Beatson West of Scotland Cancer Centre — Glasgow,
- UCL Hospitals NHS Foundation Trust — London,
- The Christie NHS Foundation Trust — Manchester,
- Newcastle Upon Tyne NHS Foundation Trust — Newcastle upon Tyne,
- Oxford University Hospitals NHS Foundation Trust — Oxford,
📞 Contact the Study Coordinator
Phone: (385) 374-1724
Email: clinicaltrials@recursionpharma.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Head and Neck Squamous Cell Carcinoma (HNSCC)
- [18F]-AraG PET Imaging in LA HNSCC — Indianapolis, Indiana
- A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma — Los Angeles, California
- SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma — Tucson, Arizona
- INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC — Duarte, California
- Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer — Pittsburgh, Pennsylvania
Explore by condition: All Head and Neck Squamous Cell Carcinoma (HNSCC) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.